SexoMBC2 Non Interventional Study

Breast Cancer Clinical Trial

— SexoMBC2  

Official title:

Sexual Quality of Life and Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05577156
• Other study ID #: 2022-A01192-41
• Status: Completed
• Start date: December 5, 2022
• Est. completion date: May 17, 2023

Study information

• Verified date: July 2023
• Source: Institut de Cancérologie de Lorraine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The study is composed of three paper self-questionnaires to be filled in by the patients included at distance (> 6 months) from their diagnosis of metastatic breast cancer, in order to limit the impact of the announcement on the filling out the questionnaires. After verification of the eligibility criteria, the medical oncologist will present the study to patients coming to the ICL for a follow-up consultation as part of their regular care. The patients will meet with a clinical research nurse so that she can explain the again and answer any questions they may have. She will also give the patients the questionnaires questionnaires and will give a presentation of the questions asked. After this meeting, the patients will be given sufficient time to reflect on, which may extend until their next visit to the ICL, in order to express, if they wish, their opposition to participating in the study. If she agrees to participate, the patient can then complete the questionnaires as well as the complementary questionnaire and place them in a closed envelope to be given to the clinical research nurse. The completion of the questionnaires will be completely anonymous. The data of those who object to the use of their data will be deleted from the database. After the completion of the questionnaires, and in order to allow a benefit for the patient, a semi-directive interview in the form of a teleconsultation with a psycho-oncologist and sexologist will be offered. The interviews are not mandatory. The time to fill in the self-questionnaires is estimated at 30 minutes and the semi-directive interview can last up to one hour. Finally, at the end of the study, as part of her subsequent care, each patient participating in the study will have the possibility to renew a teleconsultation with the psycho-oncologist and sexologist if she feels the need. As the subject of the study may generate personal questions and lead to a request for psychological and/or sexological care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: May 17, 2023
• Est. primary completion date: May 17, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major woman
• Patient with metastatic breast cancer, either initially or secondary metastatic breast cancer
• RH+/HER2- tumor
• Patient starting first line metastatic therapy or currently undergoing 1st line metastatic treatment
• Patient diagnosed with metastatic breast cancer 6 months or more
• WHO 1 or 2 patient
• Postmenopausal or not
• Patient able to understand the French language

Exclusion Criteria:

• Patient WHO>2
• Patient undergoing chemotherapy
• HER2+ or triple negative tumor
• Male
• Patient diagnosed with breast cancer less than 6 months ago
• Patient under guardianship, curatorship or safeguard of justice

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Quality of Life
• Sexual Behavior

Intervention

Behavioral:
• Self-questionnaires and semi-structured interview
Patients will fill these questionnaires : BISF-W, QLQ-C30, QLQ-BR23 and if they agree answer to a semi-structured interview composed of 5 questions

Locations

Country	Name	City	State
France	Institut de Cancerologie de Lorraine	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Cancérologie de Lorraine

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of sexual quality of life in women with HR+/HER2- metastatic breast cancer in first-line treatment	Patients will fill the questionnaire : BISF-W (Brief Index of Sexual Function for Women)	Day 0
Secondary	Assessment of overall quality of life in women with HR+/HER2- metastatic breast cancer in first-line treatment	Patients will fill the QLQ-C30 questionnaire	Day 0
Secondary	Assessment of overall quality of life in women with HR+/HER2- metastatic breast cancer in first-line treatment	Patients will fill the QLQ+BR23 questionnaire	Day 0
Secondary	Assessment of sexual and emotional intimacy	semi-structured interview composed of 5 questions	Day 0